NUZ — Neurizon Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$33.22m
- AU$26.89m
Brief: Neurizon Therapeutics Enters Global Licensing Agreement With Elanco
Brief: NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease
Brief: Neurizon Therapeutics Appoints Dan O’Connell As CFO
Brief: Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln
Brief: Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold
Brief: Neurizon Therapeutics Says US Patent Granted For NUZ-001
Australia's Neurizon Therapeutics rise on US patent approval
Australia's Neurizon Therapeutics slides after FDA puts drug application on hold
Brief: Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold
Brief: Neurizon Files Ind Application To Support Healey Als Platform Trial
Australia's Neurizon Therapeutics surges on getting OMPD for ALS drug in Europe
Brief: Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study
Brief: Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001
Australia's PharmAust rises on ALS treatment drug's entry into a trial
Brief: Pharmaust Received Firm Commitments To Raise A$10 Million
Australia's PharmAust falls on discounted placement
Brief: Pharmaust Seeks Trading Halt
Brief: Pharmaust Says Reappointed Michael Thurn As Managing Director And CEO
Brief: PharmAust Receives Orphan Drug Designation From US FDA For Monepantel